XML 42 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Discontinued Operations and Divestiture - Schedule of Financial Results of Discontinued Operations (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Aug. 29, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Interest and other, net          
Gain on divestiture       $ 52,163 $ 0
Income from discontinued operations, net of tax   $ 213,782 $ 31,208 241,266 78,872
FibroGen International [Member]          
Revenue:          
Product revenue, net   167,179 46,210 226,651 126,391
Operating costs and expenses:          
Cost of goods sold   3,761 5,371 13,454 14,820
Research and development   438 1,733 1,739 5,382
Selling, general and administrative   1,311 8,191 14,849 21,666
Total operating costs and expenses   5,510 15,295 30,042 41,868
Income from operations   161,669 30,915 196,609 84,523
Interest and other, net          
Interest expense   (1,900) (2,926) (7,816) (8,745)
Gain on divestiture $ 52,200 52,163 0 52,163 0
Interest income and other income (expenses), net   475 2,330 (2,173) 484
Total interest and other, net   50,738 (596) 42,174 (8,261)
Income before income taxes   212,407 30,319 238,783 76,262
Provision for income taxes   0 9 0 54
Investment income in unconsolidated variable interest entity   1,375 898 2,483 2,664
Income from discontinued operations, net of tax   $ 213,782 $ 31,208 $ 241,266 $ 78,872